Adaptive Biotechnologies Corp (NAS:ADPT)
$ 3.35 -0.1 (-2.9%) Market Cap: 493.69 Mil Enterprise Value: 296.04 Mil PE Ratio: 0 PB Ratio: 1.79 GF Score: 72/100

Adaptive Biotechnologies Corp at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 09:30PM GMT
Release Date Price: $62.79 (+4.16%)
Tycho W. Peterson
JPMorgan Chase & Co, Research Division - Senior Analyst

All right. Good afternoon. We're going to go ahead and take it off. I'm Tycho Peterson from the life science team. It's my pleasure to introduce our next company this afternoon, Adaptive Biotechnologies.

For those that want to submit a question, there is a link on the website. And with that, let me turn it over to Chad.

Chad M. Robins
Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman

Hey, thanks, Tycho. And thank you to JPMorgan for the opportunity to present today. I want to wish everyone a happy and healthy 2021.

Obviously, 2020 was a challenging year, but what it do is it put the world on notice about the importance of the adaptive immune system. And that's been really our sole focus at Adaptive for the last decade. And as we start the new year, start the second decade of Adaptive, we're poised to execute on our platform to power the age of immune medicine.

So as we briefly move to Slide 2, a quick reminder, this presentation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot